1.	S0820, Adenoma and Second Primary Prevention Trial Phase: Phase III Type: Prevention Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: S0820, U10CA037429, NCI-2012-02067, NCT01349881
2.	Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Approved-not yet active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: CPP-FAP-310, NCT01483144
3.	Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention Status: Active Age: 40 to 120 Sponsor: NCI Protocol IDs: NCI-2009-01192, MC054A, R01CA113681, NCT00983580
4.	Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Pharmaceutical / Industry Protocol IDs: NMTRC 003, NCT01586260
5.	Urinary Biomarker Study With Sulindac and Difluoromethylornithine Phase: Phase II Type: Diagnostic, Prevention Status: Approved-not yet active Age: 40 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: UA-UB-101, NCT01636128